{"id":"https://openalex.org/W2000383291","doi":"https://doi.org/10.1158/1535-7163.targ-09-c36","title":"Abstract C36: MBP-426, a novel liposome-encapsulated oxaliplatin, in combination with 5-FU/leucovorin (LV): Phase I results of a Phase I/II study in gastro-esophageal adenocarcinoma, with pharmacokinetics","display_name":"Abstract C36: MBP-426, a novel liposome-encapsulated oxaliplatin, in combination with 5-FU/leucovorin (LV): Phase I results of a Phase I/II study in gastro-esophageal adenocarcinoma, with pharmacokinetics","publication_year":2009,"publication_date":"2009-12-01","ids":{"openalex":"https://openalex.org/W2000383291","doi":"https://doi.org/10.1158/1535-7163.targ-09-c36","mag":"2000383291"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-09-c36","doi":"https://doi.org/10.1158/1535-7163.targ-09-c36","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-09-c36","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111839131","display_name":"Neil N. Senzer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neil N. Senzer","raw_affiliation_strings":["1 MCCRC, Dallas, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1 MCCRC, Dallas, TX;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111848586","display_name":"Kazuhiko Matsuno","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405264697","display_name":"Mebiopharm Co., Ltd. (Japan)","ror":"https://ror.org/02p73cw19","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405264697"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kazuhiko Matsuno","raw_affiliation_strings":["2 Mebiopharm Co., Ltd., Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2 Mebiopharm Co., Ltd., Tokyo, Japan;","institution_ids":["https://openalex.org/I4405264697"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045282980","display_name":"N. Yamagata","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405264697","display_name":"Mebiopharm Co., Ltd. (Japan)","ror":"https://ror.org/02p73cw19","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405264697"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Nobuyuki Yamagata","raw_affiliation_strings":["2 Mebiopharm Co., Ltd., Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2 Mebiopharm Co., Ltd., Tokyo, Japan;","institution_ids":["https://openalex.org/I4405264697"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Tadashi Fujisawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405264697","display_name":"Mebiopharm Co., Ltd. (Japan)","ror":"https://ror.org/02p73cw19","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405264697"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tadashi Fujisawa","raw_affiliation_strings":["2 Mebiopharm Co., Ltd., Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2 Mebiopharm Co., Ltd., Tokyo, Japan;","institution_ids":["https://openalex.org/I4405264697"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040540899","display_name":"Ernesto Wasserman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ernesto Wasserman","raw_affiliation_strings":["3 AAIPharma, San Antonio, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3 AAIPharma, San Antonio, TX;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110271490","display_name":"William Sutherland","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William Sutherland","raw_affiliation_strings":["4 AAIPharma, Le Kremlin Bicetre, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4 AAIPharma, Le Kremlin Bicetre, France;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108551216","display_name":"Sunil Sharma","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sunil Sharma","raw_affiliation_strings":["5 Huntsman Cancer Institute, Salt Lake City, UT;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5 Huntsman Cancer Institute, Salt Lake City, UT;","institution_ids":["https://openalex.org/I2801159745"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066360308","display_name":"Alexandria T. Phan","orcid":"https://orcid.org/0000-0002-2953-3033","observed_orcids":["https://orcid.org/0000-0002-2953-3033"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexandria Phan","raw_affiliation_strings":["6 M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6 M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":40,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"8","issue":"12_Supplement","first_page":"C36","last_page":"C36"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.7294999957084656,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.7294999957084656,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.1581999957561493,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.07880000025033951,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oxaliplatin","display_name":"oxaliplatin","score":0.843999981880188},{"id":"https://openalex.org/keywords/liposomal-chemotherapy","display_name":"liposomal chemotherapy","score":0.7699999809265137},{"id":"https://openalex.org/keywords/5-fluorouracil","display_name":"5-fluorouracil","score":0.9390000104904175},{"id":"https://openalex.org/keywords/leucovorin","display_name":"leucovorin","score":0.9980000257492065},{"id":"https://openalex.org/keywords/esophageal-adenocarcinoma","display_name":"esophageal adenocarcinoma","score":0.8100000023841858},{"id":"https://openalex.org/keywords/gastric-adenocarcinoma","display_name":"gastric adenocarcinoma","score":0.9350000023841858},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.5809999704360962},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7839999794960022},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.8930000066757202},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8500000238418579},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.8009999990463257},{"id":"https://openalex.org/keywords/enhanced-permeability-and-retention-effect","display_name":"enhanced permeability and retention effect","score":0.6660000085830688},{"id":"https://openalex.org/keywords/tumor-targeting","display_name":"tumor targeting","score":0.5830000042915344}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8220614194869995},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5987228155136108},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5851828455924988},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.532668948173523},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5246703624725342},{"id":"https://openalex.org/C43376680","wikidata":"https://www.wikidata.org/wiki/Q6580786","display_name":"Bolus (digestion)","level":2,"score":0.477642685174942},{"id":"https://openalex.org/C2779742542","wikidata":"https://www.wikidata.org/wiki/Q372701","display_name":"Esophageal cancer","level":3,"score":0.4370725154876709},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4296756982803345},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.42597877979278564},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.36548876762390137},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2867179811000824},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2719873785972595},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.18923869729042053}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-09-c36","doi":"https://doi.org/10.1158/1535-7163.targ-09-c36","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-09-c36","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.7599999904632568}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2212808007","https://openalex.org/W1922689830","https://openalex.org/W2589184047","https://openalex.org/W7122852506","https://openalex.org/W2243108850","https://openalex.org/W2106719016","https://openalex.org/W2366445581","https://openalex.org/W2240186303","https://openalex.org/W2267949276","https://openalex.org/W3049302522"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"MPB-426":[2,67],"is":[3,378],"a":[4,31,215,291],"new":[5,408],"transferrin-conjugated":[6],"liposomal":[7],"formulation":[8,409],"of":[9,26,66,79,106,207,217,264,295,410],"oxaliplatin,":[10],"which":[11,229],"can":[12],"provide":[13],"preferential":[14],"tumor":[15,147],"targeting":[16],"and":[17,24,75,100,123,179,202,240,244,268,348],"better":[18],"bioavailability":[19],"through":[20],"the":[21,49,64,77,221,306,371,379],"EPR":[22],"effect":[23],"binding":[25],"transferrin":[27],"receptors,":[28],"respectively.":[29],"In":[30],"recent":[32],"phase":[33,51,57,138,150,168],"I":[34,139,169],"study,":[35],"single":[36],"agent":[37],"MBP-426":[38,90,115,374],"given":[39,93,112],"q3w":[40,94],"showed":[41],"thrombocytopenia":[42,256],"as":[43,305],"DLT,":[44],"with":[45,70,85,103,114,160,273,328,385,406],"226":[46,99,226],"mg/m2":[47,102,128,304,377],"being":[48],"recommended":[50],"II":[52,151],"dose":[53,97,140,223,231,293,326,335,396],"(RDP2).":[54],"The":[55,137,149,167],"current":[56],"I\u2013II":[58],"study":[59],"was":[60,92,111,143,311,321,397,414],"designed":[61],"to":[62,156,313,360,363],"establish":[63],"RDP2":[65,380],"in":[68,82,145,228,315,353,383,416],"combination":[69,81,384],"5-FU/LV":[71,386],"(de":[72,387],"Gramont":[73,388],"schedule)":[74,389],"assess":[76],"efficacy":[78],"this":[80,395,407],"pretreated":[83],"patients":[84,159,175,213,284],"gastro-esophageal":[86,162],"(GE)":[87],"adenocarcinoma.":[88,165],"Methods:":[89],"IV":[91,118,131],"at":[95,220,278,290,324,375,394],"two":[96,230],"levels:":[98],"170":[101,296,303,376],"fixed":[104],"doses":[105],"5-FU/LV.":[107],"LV":[108],"(400":[109,121],"mg/m2)":[110],"concurrently":[113],"followed":[116],"by":[117,125,129],"bolus":[119],"5-FU":[120,126],"mg/m2),":[122,227],"then":[124],"2400":[127],"continuous":[130],"(CIV)":[132],"infusion":[133],"over":[134],"46":[135],"hours.":[136],"assessment":[141],"part":[142,152,170],"conducted":[144],"solid":[146],"patients.":[148,419],"will":[153,367],"be":[154,368],"limited":[155,312],"second":[157],"line":[158],"gastric,":[161],"or":[163],"esophageal":[164],"Results:":[166],"has":[171,403],"been":[172,288,404],"completed.":[173],"Nine":[174],"(pts)":[176],"were":[177,235,255,300],"included":[178],"treated.":[180],"Median":[181,205],"age:":[182],"61":[183],"years":[184],"(55\u201367),":[185],"gender":[186],"M/F:":[187],"5/4,":[188],"ECOG":[189],"PS":[190],"0/1:":[191],"2/7,":[192],"diagnosis:":[193],"colorectal":[194,356],"4,":[195],"pancreas":[196],"2,":[197],"bladder":[198],"1,":[199],"H&N":[200],"1":[201,316,349],"cervix":[203],"1.":[204],"number":[206],"prior":[208,361],"lines:":[209],"4":[210],"(2\u201310).":[211],"Four":[212],"received":[214],"total":[216],"11":[218],"cycles":[219],"first":[222],"level":[224,294],"(MBP-426":[225],"limiting":[232],"toxicities":[233,254],"(DLTs)":[234],"observed:":[236],"grade":[237,245,252,274],"3":[238,246,275,354,391],"nausea":[239],"vomiting":[241],"(1":[242,249,266,271],"pt)":[243],"back":[247],"pain":[248],"pt).":[250],"Additional":[251],"3\u20134":[253,309],"(3":[257],"pts),":[258,261],"neutropenia":[259,314],"(2":[260,351],"transient":[262],"rise":[263],"bilirubin":[265],"pt),":[267],"skin":[269],"toxicity":[270,310],"pt":[272],"erythema":[276],"multiforme":[277],"cycle":[279],"4).":[280],"To":[281],"date,":[282],"six":[283],"(7":[285],"cy)":[286],"have":[287],"explored":[289],"lower":[292],"mg/m2.":[297,338],"No":[298,400],"DLTs":[299],"observed,":[301],"establishing":[302],"RDP2.":[307],"Grade":[308],"pt.":[317],"Oxaliplatin-induced":[318],"peripheral":[319,401],"neuropathy":[320],"not":[322],"reported":[323,405],"either":[325],"level,":[327],"5":[329],"pts":[330],"receiving":[331],"an":[332],"oxaliplatin":[333],"equivalent":[334],"\u2265":[336],"500":[337],"Efficacy:":[339],"early":[340],"data":[341,366],"show":[342],"2":[343,417],"SD":[344],"(4":[345],"cycles,":[346],"4+)":[347],"PD":[350],"cycles)":[352],"evaluable":[355],"pts,":[357],"all":[358],"resistant":[359],"exposure":[362],"oxaliplatin.":[364,411],"Pharmacokinetic":[365],"available":[369],"for":[370,381],"meeting.":[372],"Conclusion:":[373],"use":[382],"every":[390],"weeks.":[392],"Treatment":[393],"well":[398],"tolerated.":[399],"neurotoxicity":[402],"Potential":[412],"activity":[413],"observed":[415],"oxaliplatin-resistant":[418],"Citation":[420],"Information:":[421],"Mol":[422],"Cancer":[423],"Ther":[424],"2009;8(12":[425],"Suppl):C36.":[426]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":3}],"updated_date":"2026-10-02T10:15:12.560889","created_date":"2016-06-24T00:00:00"}